JP Morgan Chase’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-31
| Closed | -$116 | – | 7885 |
|
|
2024
Q3 | $116 | Hold |
31
| – | – | ﹤0.01% | 6980 |
|
|
2024
Q2 | $300 | Sell |
31
-1
| -3% | -$34 | ﹤0.01% | 6737 |
|
|
2024
Q1 | $2.38K | Buy |
32
+16
| +100% | +$2.11K | ﹤0.01% | 6554 |
|
|
2023
Q4 | $2.8K | Buy |
16
+8
| +100% | +$3.94K | ﹤0.01% | 6670 |
|
|
2023
Q3 | $5.61K | Buy |
8
+2
| +33% | +$8.57K | ﹤0.01% | 6362 |
|
|
2023
Q2 | $29.3K | Buy |
6
+1
| +20% | +$3.47K | ﹤0.01% | 5837 |
|
|
2023
Q1 | $14K | Buy |
+5
| New | +$14.6K | ﹤0.01% | 6057 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 7107 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 6952 |
|
|
2022
Q2 | – | Sell |
-12
| Closed | -$31.3K | – | 6986 |
|
|
2022
Q1 | $39K | Sell |
12
-13
| -52% | -$55.9K | ﹤0.01% | 5888 |
|
|
2021
Q4 | $158K | Buy |
25
+15
| +150% | +$115K | ﹤0.01% | 5479 |
|
|
2021
Q3 | $91K | Buy |
10
+2
| +25% | +$17.2K | ﹤0.01% | 5620 |
|
|
2021
Q2 | $77K | Buy |
+8
| New | +$131K | ﹤0.01% | 5627 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 6427 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 6001 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 5853 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 5769 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 5807 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 5941 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6012 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6062 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6105 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 5983 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 5868 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 5733 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 5677 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 5398 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 4922 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 5002 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 4998 |
|
Other funds holding SEEL
JP Morgan Chase's SEEL Position: Q4 2024 in Review
JP Morgan Chase sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 31 shares — an estimated $116 sold.
JP Morgan Chase first reported a position in SEEL in Q2 2021 and held it in 11 quarters. The position peaked at $158K in Q4 2021. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.
- JP Morgan Chase reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- JP Morgan Chase sold 31 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $116.
- JP Morgan Chase first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
- JP Morgan Chase's Seelos Therapeutics, Inc. Common Stock position peaked at $158K in Q4 2021.
- 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.